Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMU1XOD)

Drug Name
Nafamostat Drug Info
Synonyms
FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
Indication
Disease Entry ICD 11 Status REF
Pancreatitis DC31-DC34 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [2]
Sepsis 1G40-1G41 Discontinued in Phase 2 [3]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [4]
Cross-matching ID
PubChem CID
4413
ChEBI ID
CHEBI:135466
CAS Number
CAS 81525-10-2
TTD Drug ID
DMU1XOD

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine protease unspecific (SP) TTEMV5X NOUNIPROTAC Inhibitor [5]
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Not Available [6]
COVID-19 spike glycoprotein (S) TTZ3COY SPIKE_SARS2 Inhibitor [7]
MERS-CoV spike glycoprotein (S) TT85VHW A0A140AYZ5_9BETC Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tumor necrosis factor (TNF) DTT TNF 5.692 3.07 4.413 1.202
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Pancreatitis
ICD Disease Classification DC31-DC34
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.51E-01 0.05 0.27
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4262).
2 ClinicalTrials.gov (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006437)
4 Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
5 Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.